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Abstract
Objective
To identify CSF parameters at diagnosis of clinically isolated syndrome (CIS) and MS that are
associated with early inﬂammatory disease activity as measured by standardized cerebral MRI
(cMRI).
Methods
One hundred forty-nine patients with newly diagnosed CIS and MS were included in the
retrospective study. cMRI at onset and after 12 months was analyzed for T2 and gadolinium-
enhancing lesions. CSF was tested for oligoclonal bands and intrathecal synthesis of im-
munoglobulin G (IgG), A (IgA), and M (IgM) before initiation of disease-modifying therapy
(DMT). In a subgroup of patients, CSF and serum samples were analyzed for sCD27,
neuroﬁlament light chain, and IgG subclasses 1 and 3. Association between CSF parameters
and cMRI activity was investigated by univariable and multivariable regression analysis in all
patients, DMT-treated patients, and untreated patients.
Results
IgG index, sCD27 levels in CSF, and to a lesser extent IgM index were associated with the
occurrence of new cMRI lesions. IgG index and sCD27 levels in CSF were highly correlated. In
a multivariable analysis, IgG index and to a lesser extent IgM index together with DMT
treatment status and gender were strongest predictors of future cMRI activity.
Conclusions
CSF parameters such as IgG and IgM index are independently associated with future MRI
activity and thus might be helpful to support early treatment decisions in patients newly
diagnosed with CIS and MS.
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MS is a chronic inﬂammatory demyelinating disease of the
CNS, often leading to accumulation of severe disability over
time. In patients presenting with a ﬁrst clinical manifestation
of MS or clinically isolated syndrome (CIS), individual dis-
ease course is still unpredictable.
Several cerebral MRI (cMRI) and CSF parameters are asso-
ciated with early and possibly long-term outcome. A high
lesion load on initial cMRI is associated with conversion from
CIS toMS1,2 and long-term outcome.3 CSF oligoclonal bands
(OCBs) were shown to be associated with a higher risk of
a second relapse and hence clinical progression from CIS to
MS.1,4,5 Other CSF parameters such as intrathecal IgM syn-
thesis, albumin ratio between CSF and blood, IgM, sCD27,
chitinase like protein 3, micro RNA, IgG subclasses, and
neuroﬁlament light chain (NFL) were shown to be associated
with conversion of CIS to MS, relapses, accumulation of brain
lesion, and disease progression.6–17
Based on these ﬁndings, the recently revised new diagnostic
MS criteria contain OCBs as a marker to demonstrate dis-
semination in time besides clinical and cMRI parameters. This
has reinforced CSF examination during the diagnostic workup
of patients with CIS and MS providing the opportunity to use
CSF parameter for predicting the course of disease.
The aim of this study was to identify and conﬁrm candidate
CSF parameters potentially associated with early in-
ﬂammatory disease activity as determined by cMRI and sug-
gest a predictive score for patients newly diagnosed with CIS
and MS. We decided to focus on parameters that are used in
standard diagnostic workup such as intrathecal immunoglo-
bulins and OCBs on the one hand and sCD27 as a marker for
inﬂammation and B-cell diﬀerentiation and NFL as a marker
for neurodegeneration on the other hand. Because early
disease-modifying therapy (DMT) treatment has a major
impact on MRI parameters, we assessed the predictive value
of the CSF biomarker in patients who did or did not receive
treatment with DMT.
Methods
Patient cohort and inclusion criteria
A total number of 149 patients with a ﬁrst manifestation of
MS/CIS from the Department of Neurology of the Technical
University of Munich were included in this retrospective
study. Patients eligible for analysis met the following criteria:
(1) ﬁrst clinical event suggestive of MS within the last 12
months at time of CSF sampling, (2) no further history of
neurologic symptoms suggestive of an earlier disease mani-
festation, (3) therapy naive regarding DMT at the time of
CSF sampling and baseline cMRI, (4) baseline cMRI with
standardized sequences 1–3 months after initial lumbar
puncture, and (5) follow-up cMRI with standardized
sequences 12 ± 3 months after baseline cMRI. One hundred
nine of 149 patients did not receive IV or oral steroid treat-
ment within 30 days before CSF sampling.
Treatment was recorded in all patients and used for stratiﬁ-
cation of subgroups. Fifty-two patients were not treated with
DMT (DMT−), and 97 patients received DMT (DMT+)
during the follow-up period. Of these patients, 63 received
β-interferons, 28 glatiramer acetate, 3 natalizumab, 2 dimethyl
fumarate, and 1 teriﬂunomide. Of the 52 patients in the
DMT− group, 29 declined treatment, 11 discontinued early
due to side eﬀects, 2 received delayed treatment after 7
months, and 2 became pregnant. In 8 patients, treatment was
not recommended by the treating physician.
The study was approved by the ethics committee of the
Technical University of Munich. Written informed consent
was obtained from every participant.
CSF and serum analysis
CSF and serum were collected during diagnostic workup
between 2008 and 2014. In a subset of patients, CSF and sera
were aliquoted and stored for later analyses at −80°C. Samples
underwent routine diagnostic analysis, which included de-
tection of OCBs through isoelectric focusing and silver
staining andmeasuring of IgG, IgM, IgA, albumin, and protein
concentrations by nephelometry. Intrathecal synthesis of
immunoglobulins (IgG, IgA, and IgM) was calculated
according to Reiber formula.18 Immunoglobulin indices were
calculated as follows: IgX-Index = [IgX (CSF)/IgX (serum)]/
[Albumin (CSF)/Albumin (serum)]. Thirteen patients un-
derwent lumbar puncture at another hospital. In this case,
externally analyzed CSF data were acquired and included in
this study. As standard diagnostic CSF workup can vary from
hospital to hospital, some parameters are missing: 2 patients
have no information regarding IgM and 6 patients re-
garding IgA.
From 84 patients, frozen CSF samples were available for
further analysis, which included testing for levels of sCD27
and NFL using commercially available ELISA kits (sCD27:
Human sCD27 Instant ELISA; eBioscience, San Diego, CA;
NFL: NF-light ELISA; UmanDiagnostics, Umea, Sweden) as
well as determining individual IgG subclass distribution by
Glossary
AUC = area under the curve; CIS = clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease modifying therapy;
NFL = neuroﬁlament;OCB = oligoclonal band; ROC = receiver operating characteristic; TE = echo time; TI = inversion time;
TR = repetition time.
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measuring levels of IgG1 and IgG3 by nephelometry (Sie-
mens BN ProSpec, Germany). As CSF has a much lower
concentration of sCD27 than serum and the applied ELISA
kit was designed for serum analysis, we did not comply to the
manufacturer’s instructions to dilute the samples 1:25 but
used undiluted CSF.
Because of small sample volumes, experiments were per-
formed in single wells. Of the 84 patients with frozen CSF
samples, 61 also had suﬃcient amounts of stored serum,
which was subsequently analyzed together with matched
CSF samples in regard to IgG1 and IgG3 levels by nephe-
lometry. IgG1 and IgG3 indices were then calculated as
above.
MRI
The ﬁrst scan (baseline cMRI) was performed 1–3 months
after lumbar puncture; the second scan (follow-up cMRI) was
performed 12 ± 3 months after baseline cMRI. Activity on
cMRI was deﬁned as the appearance of new T2 hyperintense
and/or new gadolinium enhancing lesions on follow-up
cMRI. Brain images were all acquired on the same 3 T Philips
scanner.
The scanning protocol included 3D gradient echo (GRE) T1-
weighted (w) sequence before and after gadolinium injection
(orientation, 170 contiguous sagittal 1 mm slices; ﬁeld of
view, 240 × 240 mm; voxel size, 1.0 × 1.0 mm; repetition time
[TR], 9 ms; echo time [TE], 4 ms) and 3D ﬂuid attenuated
inversion recovery (FLAIR) sequence (orientation, 144
contiguous axial 1.5 mm slices; ﬁeld of view, 230 × 185 mm;
voxel size, 1.0 × 1.5 mm; TR, 10,000 ms; TE, 140 ms; in-
version time, 2,750 ms).
Baseline cMRI data were analyzed in regard to lesion count,
lesion load, and existence of gadolinium enhancing lesions.
T2-hyperintense lesions were segmented from FLAIR and
T1-weighted images by a lesion growth algorithm19 as
implemented in the lesion segmentation tool toolbox version
2.0.15 (statistical-modelling.de/lst.html) for SPM12 (ﬁl.ion.
ucl.ac.uk/spm). Seven cMRIs (4.7%) did not follow our
standardized protocol and were thus excluded.
Statistical analysis
The distribution of quantitative data is described by median
and range. Qualitative data are presented by absolute and
relative frequencies. Associations of potential risk factors to
the binary outcome cMRI activity are analyzed by univariable
and multivariable logistic regression models and quantiﬁed by
respective ORs with 95% CIs. Univariable models were ﬁt to
the whole study cohort while inclusion of an interaction term
between the respective risk factor and a dummy variable
coding DMT+ and DMT− patients allowed to estimate eﬀect
sizes within and to test the diﬀerence between these sub-
groups. The multivariable model made use of gender, DMT,
OCBs, IgG, IgM, IgA (indices and synthesis), lesion volume,
and lesion count in a stepwise forward variable selection that
was based on Akaike’s information criterion. The prognostic
strength of the resulting model was assessed by the area under
the curve (AUC) of the receiver operating characteristic
(ROC) curve. Further multivariable models were ﬁt in
a separate analysis to assess the additional prognostic value
of CSF. Therefore a baseline model including gender, DMT,
lesion volume, and lesion count in the baseline cMRI was
compared against another model that extended this list of
covariates to include further CSF parameters such as OCBs,
IgG, IgM, and IgA (indices and synthesis). The diagnostic
strength of the models was again quantiﬁed by the AUC. The
diﬀerence was tested by a likelihood ratio test of these nested
models. To depict the correlation between sCD27 and IgG
index, we used Pearson correlation coeﬃcient. All analyses
were performed using R 3.5.0 (The R Foundation for Sta-
tistical Computing, Vienna, Austria). Hypothesis testing was
conducted on exploratory 2-sided 5% signiﬁcance levels. As
this was an exploratory study, we did not correct for multiple
comparisons.
Data availability statement
The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request. The
data are not publicly available to protect the privacy of the
participating patients.
Results
Study cohort
From the 149 patients analyzed in our retrospective study, 52
patients did not start DMT within 6 months after baseline
cMRI or discontinued medication again after less than 6
months. The remaining 97 patients received DMT for at least
6 months. DMT+ and DMT−patients were comparable in
regard to age, sex distribution, and time between symptom
onset and ﬁrst MRI (table 1). In 81 patients, we observed
disease activity by cMRI between the baseline and follow-up
scan after 12 months.
Intrathecal IgG, IgM, and IgA synthesis
We analyzed the association between intrathecal IgG syn-
thesis determined by the IgG index and the occurrence of new
MRI lesions by logistic regression. The IgG index was asso-
ciated with new cMRI lesions after 12 months (OR 3.441,
CI 1.482–9.206; p = 0.008, table 2). When we stratiﬁed the
cohort according to DMT treatment, the eﬀect was more
pronounced in the DMT− patients (OR 32.021, CI
1.574–651.251; p = 0.024) than DMT+ patients (OR 2.090,
CI 0.787–5.553; p = 0.139, table 2). We also determined
intrathecal IgG synthesis using Reiber formula. Intrathecal
IgG synthesis was observed in 50% of patients. DMT−
patients with intrathecal IgG synthesis had a higher risk of
cMRI activity compared to those without intrathecal synthesis
(OR 11.528, CI 2.237–59.399; p = 0.003) (table 3 and ﬁgure
1). This eﬀect was also seen in all patients (OR 1.517, CI
0.776–2.995; p = 0.225). In DMT+ patients intrathecal IgG
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synthesis was not associated with cMRI activity (OR 0.742,
CI 0.332–1.661; p = 0.468, table 3).
Analysis of the relation of intrathecal IgM synthesis on cMRI
activity showed that a higher IgM index was associated with
cMRI activity after 12months (OR 43.370, CI 1.177–2,914.982;
p = 0.056) (table 2). The eﬀect wasmore pronounced inDMT−
patients (OR after correction by Firth method 5,970.034, CI
0.508–70098464.401; p = 0.069) than DMT+ patients (OR
5.092, CI 0.065–396.140; p = 0.464) (table 2). We stratiﬁed
patients into those with and without intrathecal IgM synthesis
according to Reiber formula. Overall 14% of patients had in-
trathecal IgM synthesis. Of the 20 patients with intrathecal IgM
synthesis, 15 showed cMRI activity in the follow-up scan (OR
2.861, CI 0.993–9.572; p = 0.064) (table 3 and ﬁgure 1). All 9
DMT− patients with intrathecal IgM showed cMRI activity
during the ﬁrst 12 months (OR 11.630, CI 0.544–248.843; p =
0.116) but only 6 out of 11 in DMT+ patients (table 3).
We found a negative association of the IgA index with cMRI
activity in DMT+ patients and only a marginal positive eﬀect in
DMT− patients (table 2). Intrathecal IgA synthesis according
to Reiber formula was detected in only 8% of all patients (n =
11) and was negatively associated with a higher risk for cMRI
activity regardless of treatment status (table 3 and ﬁgure 1).
In a subgroup of patients, we analyzed the IgG subclasses 1
and 3 in CSF as well as respective indices (table 2).
We found that elevated IgG1 indices were positively associ-
ated with cMRI progression (OR 1.391, CI 0.645–3.314; p =
0.416). This eﬀect was more pronounced in DMT− patients
(OR 9.876, CI 0.503–194.019; p = 0.132) but not in DMT+
patients (OR 0.780, CI 0.279–2.179; p = 0.636). Elevated
IgG1 levels in CSF were associated with a higher risk of cMRI
activity (OR 1.023, CI 1.003–1.048; p = 0.039). The eﬀect was
stronger in DMT− patients than DMT+ patients (table 2).
In all patients, IgG3 indices were not associated with cMRI
progression (OR 1.001, CI 0.086–13.063; p = 0.999). In-
dependent analysis of DMT+ and DMT− patients showed
a positive association in untreated patients (OR 2.558, CI
Table 1 Baseline characteristics of patient cohorts
MS/CIS all MS/CIS DMT2 MS/CIS DMT+
Demographic data
No. of patients [n] 149 52 97
Sex female [n (%)] 101 (68) 32 (62) 69 (71)
Age [median (range)] 33 (18–55) 33.5 (19–52) 33 (18–55)
Median time symptom onset to cMRI [d (range)] 67 (1–345) 64.5 (1–230) 67 (1–345)
Patients with MRI progression [n (%)] 81 (54) 37 (71) 44 (45)
cMRI data
Lesion volume [median (mL) (range)] 2.106 (0.093–35.872) 1.489 (0.093–26.762) 2.383 (0.140–35.872)
Lesion number > 9 [n (%)] 93 (62) 26 (50) 67 (69)
Impaired blood CSF barrier [n (%)] 40 (27) 12 (23) 28 (29)
T2 lesion increment [median (range)] 1 (0–15) 1 (0–8) 0 (1–15)
CSF data
OCB + [n (%)] 116 (78) 38 (67) 78 (80)
Intrathecal IgG [n (%)] 75 (50) 25 (48) 50 (52)
Intrathecal IgM [n (%)] 20 (14) 9 (17) 11 (12)
Intrathecal IgA [n (%)] 11 (8) 7 (14) 4 (4)
IgG index [median (range)] 0.74 (0.25–3.20) 0.74 (0.41–2.69) 0.74 (0.25–3.20)
IgM index [median (range)] 0.08 (0.00–0.67) 0.08 (0.00–0.67) 0.08 (0.00–0.51)
IgA index [median (range)] 0.27 (0.00–0.80) 0.28 (0.19–0.65) 0.26 (0.00–0.80)
Cell count [median (/μl) (range)] 7 (0–126) 10 (0–126) 6 (0–46)
Abbreviations: CIS = clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease-modifying therapy; OCB = oligoclonal band.
Patients with MS/CIS were divided into 3 groups: all patients, patients with, and patients without DMT. These were compared regarding demographic, MRI,
and CSF data.
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Table 2 Comparison of cMRI progression risk in patients with MS/CIS in regard to CSF laboratory findings
MS/CIS
All patients DMT2 DMT+
MRI+/MRI2 MRI+/MRI2 MRI+/MRI2
IgG index
Median 0.81/0.69 0.81/0.53 0.74/0.73
p Value 0.008 0.024 0.139
OR 3.441 32.021 2.090
CI 1.482–9.206 1.574–651.251 0.787–5.553
p Value of interaction 0.091
IgM index
Median 0.09/0.07 0.1/0.05 0.08/0.08
p Value 0.056 0.069a 0.464a
OR 43.370 5,970.034a 5.092a
CI 1.177–2,914.982 0508–70098464.401a 0.065–396.140a
p Value of interaction 0.145
IgA index
Median 0.27/0.26 0.28/0.25 0.26/0.26
p Value 0.884 0.990 0.847
OR 0.781 1.035 0.662
CI 0.027–23.249 0.004–254.431 0.010–44.463
p Value of interaction 0.899
IgG1 index
Median 0.63/0.62 0.72/0.58 0.6/0.66
p Value 0.416 0.132 0.636
OR 1.391 9.876 0.780
CI 0.645–3.314 0.503–194.019 0.279–2.179
p Value of interaction 0.115
IgG1 (mg/L)
Median 27.85/23.2 35/19.55 25.3/24.4
p Value 0.039 0.052 0.338
OR 1.023 1.059 1.012
CI 1.003–1.048 1.000–1.122 0.988–1.036
p Value of interaction 0.149
IgG3 index
Median 0.34/0.34 0.39/0.33 0.34/0.39
p value 0.999 0.581 0.385
OR 1.001 2.558 0.141
CI 0.086–13.063 0.091–71.672 0.002–11.719
p Value of interaction 0.305
IgG3 (mg/L)
Continued
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0.091–71.672; p = 0.581) but not DMT+ patients (OR 0.141,
CI 0.002–11.719; p = 0.385).
OCBs
OCBs were positively associated with the occurrence of cMRI
activity after 12 months in the entire cohort (OR 1.855, CI
0.824–4.279; p = 0.139) and in particular in DMT− patients
(9.327, CI 2.296–37.890; p = 0.002) but not DMT+ patients
(OR 0.714, CI 0.260–1.960; p = 0.513) (table 3). Of 38
DMT− patients with OCBs, 32 patients (84%) showed new
lesions in the follow-up cMRIs, whereas only 5 out of 14
patients without OCBs (36%) (ﬁgure 1).
CSF, NFL, and sCD27 levels
We compared patients with and without cMRI activity during
the ﬁrst 12 months after diagnosis in regard to their levels of
sCD27 in CSF and found that elevated sCD27 levels were
associated with a higher risk of developing new lesions in
cMRI (table 2). Patients with higher levels of sCD27 in CSF
had a higher risk of new cMRI lesions during the follow-up
period (OR 1.552, CI 1.087–2.430; p = 0.030). The same
trend was seen in DMT− patients (OR 2.619, CI
0.875–7.842; p = 0.085) and to a lower extent in DMT+
patients (table 2). Interestingly, sCD27 levels were highly
correlated with IgG index (r = 0.884, p = 1.916 × 10−20). CSF
NFL levels showed a marginal positive association in our
cohort with new cMRI activity after 12 months regardless of
treatment status (table 2).
Multivariable analysis of CSF laboratory in
all patients
We performed a multivariable logistic regression analysis to
identify parameters that were mutually associated with MRI
progression. Because of sample size, we decided to focus on
the entire cohort and did not analyze DMT+ and
DMT−patients independently. We also did not include
sCD27 because data were only available on a subgroup of
patients and sCD27 strongly correlated with the IgG index.
IgG index, DMT, gender distribution, IgM index, and in-
trathecal IgA synthesis were selected into the model as the
most important variables (table 4). Higher IgG indices were
found to be associated with a higher risk of cMRI progression
Table 2 Comparison of cMRI progression risk in patients with MS/CIS in regard to CSF laboratory findings (continued)
MS/CIS
All patients DMT2 DMT+
MRI+/MRI2 MRI+/MRI2 MRI+/MRI2
Median 0.77/0.68 0.68/0.65 0.8/0.7
p Value 0.683 0.397 0.673
OR 1.130 1.601 0.826
CI 0.643–2.193 0.539–4.758 0.339–2.012
p Value of interaction 0.356
sCD27 (U/mL)b
Median 11.72/9.26 14.55/5.36 11.5/10.12
p Value 0.030 0.085 0.200
OR 1.552 2.619 1.335
CI 1.087–2.430 0.875–7.842 0.858–2.075
p Value of interaction 0.262
NFL (pg/mL)c
Median 1620.84/644.12 1959.55/676.52 1524.98/634.4
p Value 0.324 0.425 0.541
OR 1.033 1.047 1.025
CI 0.971–1.107 0.936–1.170 0.947–1.109
p Value of interaction 0.765
Abbreviations: CIS = clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease-modifying therapy; NFL = neurofilament.
Patients with MS/CIS were divided into 3 groups: all patients, patients with DMT (DMT+) and patients without DMT (DMT−). Patients were compared in their
risk for cMRI progression when regarding levels of immunoglobulin indices and concentrations of IgG subclasses 1 and 3, sCD27, and NFL by logistic
regression.
a Corrected by Firth method.
b For a 10 unit change.
c For a 500 unit change.
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(OR 3.144, CI 1.156–8.554; p = 0.025). As expected, DMT
was also associated with an decreased risk of cMRI activity.
Surprisingly in our cohort, female gender was associated with
a higher risk of cMRI activity. Mean IgM indices were higher
in patients with cMRI progression than in patients without
(OR 115.834, CI 0.923–14,531.160; p = 0.054). Intrathecal
IgA synthesis was associated with less cMRI activity when
using a multivariable analysis (OR 0.274, CI 0.058–1.292; p =
0.10172). The ROC analysis resulted in an AUC of 0.734 (p <
0.001), which underlines the prognostic beneﬁt of these
variables (ﬁgure 2A).
Prognostic value of cMRI vs CSF findings
To emphasize the additional prognostic value of CSF
parameters in comparison to cMRI data, we computed 2
additional multivariable models. Gender, DMT, lesion vol-
ume, and lesion count in the baseline cMRI resulted in
a model with an AUC of 0.679. Combined analysis with CSF
parameters such as OCBs, intrathecal IgG, IgM, IgA synthesis,
and their respective indices increased the prognostic strength
of the model to an AUC of 0.751 (p = 0.025) (ﬁgure 2B).
Quantitative prediction of cMRI activity
To estimate a patient’s individual risk for future cMRI ac-
tivity, we computed a numeric risk scale using the re-
gression parameters of our multivariable model (ﬁgure 3).
Values of each factor are assigned to a speciﬁc number of
points and addition of these leads to a cumulative score.
This score then can be converted to predict the patient’s
probability of future cMRI activity.
Discussion
In the present study, we investigated the predictive value of
CSF parameters at the time of diagnosis of CIS and MS for
the development of new lesions on a follow-up cMRI after
12 months.
Table 3 Risk of cMRI progression in patients with and without intrathecal immunoglobulin synthesis and OCBs
MS/CIS
All patients DMT2 patients DMT+ patients
MRI+/2 MRI+/2 MRI+/2
Patients with IgG synthesis [n (%)] 44 (54%)/31(46%) 23 (62%)/2(13%) 21 (48%)/29(55%)
p Value 0.225 0.003 0.468
OR 1.517 11.528 0.742
CI 0.776–2.995 2.237–59.399 0.332–1.661
p Value of interaction 0.003
Patients with IgM synthesis [n (%)] 15(19%)/5(8%) 9(24%)/0(0%) 6(14%)/5(10%)
p Value 0.064 0.116a 0.511a
OR 2.861 11.630a 1.533a
CI 0.993–9.572 0.544–248.843a 0.428–5.489a
p Value of interaction 0.135
Patients with IgA synthesis [n (%)] 6(7%)/5(8%) 5(14%)/2(14%) 1(2%)/3(6%)
p Value 0.516 0.937 0.390
OR 0.648 0.931 0.364
CI 0.171–2.496 0.159–5.471 0.036–3.649
p Value of interaction 0.527
Patients with CSF OCBs [n (%)] 66(82%)/50(74%) 32(86%)/6(40%) 34(77%)/44(83%)
p Value 0.139 0.002 0.513
OR 1.855 9.327 0.714
CI 0.824–4.279 2.296–37.890 0.260–1.960
p Value of interaction 0.004
Abbreviations: CIS = clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease-modifying therapy; OCB = oligoclonal band.
Patients with MS/CIS were divided into 3 groups: all patients, patients with DMT (DMT+), and patients without DMT (DMT−). Patients were compared in their
risk for cMRI progression when regarding intrathecal immunoglobulin G, M, and A synthesis and presence of OCBs by logistic regression.
a Corrected by Firth method.
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Routine diagnostic workup of patients with CIS/MS usually
entails the detection of IgG either in form of OCBs or
quantitative intrathecal synthesis as shown by IgG index
(usually > 0.7) or Reiber formula. Many labs also measure
IgM and IgA levels in CSF. As mentioned above in particular
intrathecal IgG synthesis seems to be associated with earlier
inﬂammatory disease activity leading to our inclusion of
these parameters in this study. sCD27 is the soluble version
of the surface molecule CD27 that belongs to the TNF-
receptor family and can be found on B- and T-cells. It plays
an important role in B-cell diﬀerentiation and immuno-
globulin synthesis. Because patients with MS were found to
have higher levels of the soluble version of this molecule,20
we also included this parameter in our analysis. The same
applies to NFL, which has been shown to be associated with
neuronal damage and brain atrophy in patients with
relapsing-remitting MS.12,13,21–23
We demonstrate that soluble CD27 levels in CSF, IgG1 levels,
IgG index, and possibly IgM index at the time of diagnosis are
associated with cMRI activity during the next 12 months in
our retrospective study. In the subgroup of patients who had
not been treated with DMT, sCD27, IgG1 levels, OCBs in
CSF, IgG and possible IgM indices are associated with future
cMRI activity. In the multivariable analysis, IgG index, IgM
index, and intrathecal IgA synthesis, besides DMT treatment
status and gender, are the main variables predicting future
cMRI activity in our cohort.
Until now, CSF examination in patients presenting with
suspected CIS or MS mainly serves diagnostic purposes,
which might be at least partially due to the lack of studies
systematically analyzing CSF parameters in patients present-
ing with a ﬁrst clinical event suggestive of MS. Most studies
conducted in the past dealing with a potentially prognostic
value of CSF parameters did not discriminate between
patients who started DMT during follow-up and those who
did not. In our cohort, DMT has an inﬂuence on cMRI ac-
tivity even within a short follow-up period of 12 months,
which is in line with many previous studies.1,24–28 For this
Figure 1 Intrathecal immunoglobulin synthesis and OCBs in CSF
The number of patients with and without intrathecal IgG, IgM,
and IgA synthesis and oligoclonal bands are shown and com-
pared regarding cMRI progression during the first 12 months.
White columns = patients with new lesions. Black columns =
patients without new lesions. (A) All patients, (B) only patients
without DMT, and (C) only patients receiving DMT. DMT = dis-
ease-modifying therapy; OCB = oligoclonal band.
Table 4 Multivariable analysis of CSF laboratory findings
in all patients
p Value OR CI
IgG index 0.025 3.144 1.156–8.554
DMT 0.002 0.249 0.105–0.594
Gender 0.028 2.506 1.107–5.672
IgM index 0.054 115.834 0.923–14,531.16
Intrathecal IgA synthesis 0.102 0.274 0.058–1.292
Abbreviations: CIS = clinically isolated syndrome; DMT = disease-modifying
therapy.
Potentially prognostic biomarkers in patients with MS/CIS were analyzed by
multivariable logistic regression to obtain p-values, OR, and CI.
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reason, we decided to discriminate between patients with and
without DMT to exclude the eﬀect of this confounding factor.
Moreover, in the studies conducted so far, progression has been
mainly deﬁned by clinical outcome parameters, and follow-up
time periods varied largely even within patient cohorts. As
clinical relapses are sometimes challenging to discern precisely
from anamnestic information in clinical routine and calculation
of Expanded Disability Status Scale (EDSS) scores (especially
of lower values) varies from day to day depending on a patient’s
physical state as well as the individual examiner, we concluded
that MRI oﬀers a more sensitive and objective parameter to
detect disease activity, especially when MRI scanning is per-
formed in a highly standardized fashion.
Overall our ﬁndings are in line with previous studies sug-
gesting a predictive role of intrathecal IgG synthesis, IgM
synthesis, and the presence of OCBs for predicting future
clinical disease activity. The presence of OCBs in the CSF is
a known risk factor for conversion to MS in patients with
CIS.1,2,5 The same applies to quantitative measures of IgG and
IgM synthesis in the CSF compartment.29 Little is known
about how IgG1 and IgG3 levels in serum and CSF relate to
future disease activity. Increased IgG1 levels in CSF are found in
patients with CIS and MS.30,31 We observed an association of
IgG1 levels in CSF and future MRI activity. However, this
analysis was based on only a smaller subset of our cohort and the
IgG1 index itself may have shown a positive association with
cMRI activity but failed to reach the level of signiﬁcance. A recent
study reported an association of higher serum IgG3 levels with
faster conversion to MS in patients with CIS.32 However, this
study was based on a small cohort of patients. We did observe
a slight positive association of IgG3 levels in CSF with MRI
activity; however, once again this trend failed to reach signiﬁ-
cance. Also sCD27 levels in CSF seem to be associated with
conversion to MS and future relapse activity in adults and chil-
drenwithCIS.9,33Our ﬁndings of an association between sCD27
in CSFwithMRI activity are in line with these studies. However,
IgG index and sCD27 levels in CSF are highly correlated sug-
gesting that they are not independent biomarkers and rather
depict markers of humoral inﬂammation in the CNS compart-
ment. Most studies reported NFL in CSF or serum as a pre-
dictive marker for future disease activity.16,34 Although we
observed a trend in the same direction, the eﬀect was small in our
study and did not reach the level of signiﬁcance, which might be
due to the low number of patients in the NFL analysis.
In summary, we provide evidence that IgG index and to a lesser
extent IgM and IgA index are helpful markers to predict future
MRI activity in particular if they are combined with other vari-
ables such as DMT status and gender distribution. Establishing
reliable risk scores for patients with newly diagnosed CIS or MS
might be very helpful to guide early treatment decisions. Such
a risk scoremight include other biomarkers (e.g., microRNA and
chitinase-like protein14,16,17) or imaging parameters (e.g., spinal
MRI35). As our cohort only entails a small number of patients,
further studies with larger cohorts are warranted to validate these
ﬁndings.
Figure 2Multivariable analysis of CSF parameters in regard to cMRI progression
(A) Analysis of potentially prognostic biomarkers inpatients with MS/CIS throughmultivariable logistic regression lead to selection of IgG index, DMT, gender
distribution, IgM index, and intrathecal IgA synthesis. A ROC analysis resulted in an AUC of 0.734 (p < 0.001). (B) The prognostic value of cMRI parameters
including cMRI lesion load and lesion volume and baseline information such as gender distribution and DMT were compared to the additional prognostic
value when including CSF parameters and shown in an ROC curve. AUC of MRI parameters alone was 0.679, AUC of MRI and CSF parameters combined was
0.751 (p = 0.03). AUC = area under the curve; CIS = clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease-modifying therapy; ROC = receiver
operating characteristic.
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Figure 3 Risk calculator (nomogram) for future cMRI activity in patients with MS/CIS
Potential risk factors such as IgG index, DMT, gender, IgM index, and intrathecal IgA synthesis were converted to numeric values to calculate a combined risk
score to the evaluate individual risk of future cMRI activity. (A) Scoring of individual risk factors; (B) combined risk score and risk of future cMRI activity. CIS =
clinically isolated syndrome; cMRI = cerebral MRI; DMT = disease-modifying therapy.
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